The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) are recommending a pause in the use of Ixchiq® (Chikungunya Vaccine, Live) in individuals 60 years of age and older while the Agencies investigate postmarketing reports of serious adverse events, including neurologic and cardiac events, in individuals who have received the vaccine.

As of May 7, 2025, 17 serious adverse events, including two that resulted in death, have been reported in individuals 62 through 89 years of age who received Ixchiq during postmarketing use globally. Six of these reports have been from the United States (U.S.). Most U.S. and foreign serious adverse events that have been reported to the Vaccine Adverse Event Reporting System (VAERS), co-managed by FDA and CDC, have been in individuals with underlying chronic medical conditions. Adverse events reported to VAERS may not be causally related to vaccination. Approximately 80’000 doses of Ixchiq® have been distributed globally.

More details, see LINK. For the statement of the European Medicines Agency (EMA) see EpiNews as of 8 May 2025.